News
The growing prevalence of chronic diseases is a major factor driving revenue growth in the natural killer (NK) cell ...
Inmagene enrolls first patient in ADAPTIVE phase 2b clinical trial of IMG-007: San Diego Friday, July 4, 2025, 15:00 Hrs [IST] Inmagene Biopharmaceuticals (Inmagene), a clinical-s ...
New research from UC Davis Comprehensive Cancer Center has uncovered an evolutionary change that may explain why certain ...
AbbVie has announced that it will be expanding its immunology capabilities by acquiring Capstan Therapeutics for up to $2.1bn ...
AbbVie has announced a definitive agreement to acquire Capstan Therapeutics, a clinical-stage biotechnology company, for up ...
I-Mab (NASDAQ: IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced publication of the ...
AbbVie (NYSE: ABBV) and Capstan Therapeutics, Inc. ("Capstan"), a clinical-stage biotechnology company dedicated to advancing in vivo engineering of cells through RNA delivery using tLNPs, today ...
During early drug development and preclinical development, researchers use in vitro cultured lymphocytes to induce cytokine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results